Jingwen Tan1,2, Sunjae Bae2, Jodi B Segal1,3,4,5, Junya Zhu5, Dorry L Segev2, G Caleb Alexander1,3,4, Mara McAdams-DeMarco6,7,8. 1. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615, N. Wolfe St, W6033, Baltimore, MD, 21205, USA. 2. Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA. 3. Center for Drug Safety and Effectiveness,, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 4. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA. 5. Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 6. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 615, N. Wolfe St, W6033, Baltimore, MD, 21205, USA. mara@jhu.edu. 7. Department of Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USA. mara@jhu.edu. 8. Center for Drug Safety and Effectiveness,, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. mara@jhu.edu.
Abstract
BACKGROUND: There is increasing evidence questioning the use of warfarin for atrial fibrillation (AF) among older adults with end stage renal disease (ESRD). We assessed the patterns and determinants of warfarin utilization among these patients in the US. METHODS: We assembled a cohort of older adults (age ≥65) undergoing dialysis with incident AF from July 2007 to November 2011 from the US Renal Data System (USRDS). We used descriptive statistics to characterize warfarin utilization within 30 days of AF discharge, and logistic regression to quantify patient characteristics associated with warfarin initiation. RESULTS: Among 5730 older adults undergoing dialysis with incident AF, 15.5% initiated warfarin. Among 2906 patients with high risk of bleeding, 12.7% initiated warfarin; whereas 14.9% initiated warfarin among 4824 patients with high risk of stroke. After adjustment for patient characteristics, warfarin initiation was lower among patients who were older [odds ratio (OR) = 0.74 per 10-year increase, 95% confidence interval (CI) 0.66-0.83] and those with a history of diabetes (OR = 0.75, 95% CI 0.63-0.90), myocardial infarction (OR = 0.64, 95% CI 0.50-0.80), or bleeding (OR = 0.63, 95% CI 0.50-0.80). There was no association between sex, race, or dialysis modality and warfarin initiation. Among patients who initiated warfarin, 46.8% discontinued warfarin use after a median treatment length of 8.6 months. CONCLUSION: Despite the unclear benefit and increased bleeding risk of warfarin treatment in patients with ESRD, 1 in 8 older adults undergoing dialysis with incident AF in the US who had high risk of bleeding used warfarin. Changes to warfarin therapy due to discontinuation were common after initiation.
BACKGROUND: There is increasing evidence questioning the use of warfarin for atrial fibrillation (AF) among older adults with end stage renal disease (ESRD). We assessed the patterns and determinants of warfarin utilization among these patients in the US. METHODS: We assembled a cohort of older adults (age ≥65) undergoing dialysis with incident AF from July 2007 to November 2011 from the US Renal Data System (USRDS). We used descriptive statistics to characterize warfarin utilization within 30 days of AF discharge, and logistic regression to quantify patient characteristics associated with warfarin initiation. RESULTS: Among 5730 older adults undergoing dialysis with incident AF, 15.5% initiated warfarin. Among 2906 patients with high risk of bleeding, 12.7% initiated warfarin; whereas 14.9% initiated warfarin among 4824 patients with high risk of stroke. After adjustment for patient characteristics, warfarin initiation was lower among patients who were older [odds ratio (OR) = 0.74 per 10-year increase, 95% confidence interval (CI) 0.66-0.83] and those with a history of diabetes (OR = 0.75, 95% CI 0.63-0.90), myocardial infarction (OR = 0.64, 95% CI 0.50-0.80), or bleeding (OR = 0.63, 95% CI 0.50-0.80). There was no association between sex, race, or dialysis modality and warfarin initiation. Among patients who initiated warfarin, 46.8% discontinued warfarin use after a median treatment length of 8.6 months. CONCLUSION: Despite the unclear benefit and increased bleeding risk of warfarin treatment in patients with ESRD, 1 in 8 older adults undergoing dialysis with incident AF in the US who had high risk of bleeding used warfarin. Changes to warfarin therapy due to discontinuation were common after initiation.
Entities:
Keywords:
Anticoagulants; Atrial fibrillation; Drug utilization; End stage renal disease; Warfarin
Authors: Mitesh Shah; Meytal Avgil Tsadok; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Elham Rahme; Karin H Humphries; Jack V Tu; Hassan Behlouli; Helen Guo; Louise Pilote Journal: Circulation Date: 2014-01-22 Impact factor: 29.690
Authors: Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy Journal: Circulation Date: 2014-03-28 Impact factor: 29.690
Authors: Mara A McAdams-DeMarco; Jingwen Tan; Megan L Salter; Alden Gross; Lucy A Meoni; Bernard G Jaar; Wen-Hong Linda Kao; Rulan S Parekh; Dorry L Segev; Stephen M Sozio Journal: Clin J Am Soc Nephrol Date: 2015-11-16 Impact factor: 8.237
Authors: Salima Juma; Benjamin K A Thomson; Charmaine E Lok; Catherine M Clase; Peter G Blake; Louise Moist Journal: BMC Nephrol Date: 2013-08-13 Impact factor: 2.388
Authors: Luca Di Lullo; Giovanni Tripepi; Claudio Ronco; Antonio De Pascalis; Vincenzo Barbera; Antonio Granata; Domenico Russo; Biagio Raffaele Di Iorio; Ernesto Paoletti; Maura Ravera; Maria Fusaro; Antonio Bellasi Journal: J Nephrol Date: 2018-06-07 Impact factor: 3.902